Amarin Corp Plc (AMRN)

[biotechtrader2020]

1) How is generics selling Generic Vascepa for RI indication, after invalidating a MARINE (not RI) patent, does not make a complete mockery out of the legal / regulatory system?
Drug companies have been making a mockery out of this system for years by extending life of patents. unfortunately amarin is receiving the wrong end of the stick in this case.

Doctors will write a prescription for vascepa. Insurers and pharmacists, who don't have insights into the patient's triglyceride level will substitute this with generics. The patient walks away paying just a few dollars for generic vascepa. As an investor you lose and the patient wins - the sooner you wake up to this new reality, the better it is.


2)Completely different population, of 19 men?!
If they had included women, you would have complained about not having transgendered participants. If they were included too, we can always include these additional genders to whine about and cry foul:
https://dudeasks.com/how-many-genders-are-there-in-2020/

The issue is not whether it was open label or whether it was peer reviewed.
Amarin filed for 20+ patents with a study of 229 participants (4g,2g or placebo) and Mori (4g epa, dha or olive oil) did a study on 59 participants.

Mori's conclusion - EPA did not impact LDL but decreased HDL (JL pointed out that back then it was believed that decreased HDL adversely impacts cardiovascular risk).

Judge Du is claiming that someone with ordinary skill in the art can read mori's paper and come to the conclusion that EPA is beneficial as described in Amarin's patent.


Reality check: We (including myself) have confirmation bias. We are in the denial stage where we are refusing to admit that this could have happened to us.

But here is a silver lining in the denial. This has turned raf from a guy who was insensitive to the plight of hundreds of thousands of coronavirus patients to a champion of woman's rights. I have to thank Honorable judge Du for that.



3)BP buys us at a 50% discount ($10B)

Management's current plan:
1. Litigate for 2 more years
2. Dilute share count and give millions in share grants to execs and do periodic insider sales.
3. Diligently burn shareholder value.

BP will buy us in a firesale at a fraction of that price or will walk away as the generics take over and this management burns shareholder value.